| Symbol | ANTX |
|---|---|
| Name | AN2 THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1800 EL CAMINO REAL,SUITE D, MENLO PARK, California, 94027, United States |
| Telephone | +1 650 331-9090 |
| Fax | — |
| — | |
| Website | https://www.an2therapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001880438 |
| Description | AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Additional info from NASDAQ: |
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
Read more(90% Positive) AN2 THERAPEUTICS, INC. (ANTX) Announces Enrollment Update for attainable Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
Read moreWilliams Sarah Joanne 🔴 sold 265 shares of AN2 Therapeutics, Inc. (ANTX) at $4.43 Transaction Date: May 29, 2026 | Filing ID: 253622
Read moreAN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Read moreNew Form SCHEDULE 13G/A - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0002073679-26-000066 <b>Size:</b> 6 KB
Read more(30% Negative) AN2 THERAPEUTICS, INC. (ANTX) Reports Q2 2026 Financial Results
Read moreAN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Read moreAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Read moreNew Form ARS - AN2 Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001193125-26-170328 <b>Size:</b> 796 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07301320 | Epetraborole in Patients With Mycobacterium Abscessus Lung Disease | Phase2 | Mycobacterium Abscessus Infection | Recruiting | 2026-03-30 | 2028-05-01 | ClinicalTrials.gov |
| NCT07024589 | First-in-Human Trial of Oral AN2-502998 | Phase1 | Healthy Volunteers | Completed | 2025-08-04 | 2026-03-14 | ClinicalTrials.gov |
| NCT06089668 | An Observational Study to Evaluate Clinical Characteristics of Adult Patients W… | — | Melioidosis | Completed | 2023-11-01 | 2025-02-02 | ClinicalTrials.gov |
| NCT05995444 | A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adu… | Phase1 | Healthy Volunteers | Completed | 2023-06-05 | 2023-08-03 | ClinicalTrials.gov |
| NCT05327803 | Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease | Phase2 | MAC Lung Disease | Terminated | 2022-05-20 | 2024-12-18 | ClinicalTrials.gov |
| NCT05283746 | A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function | Phase1 | Renal Insufficiency | Completed | 2022-02-21 | 2022-06-27 | ClinicalTrials.gov |
| NCT04892641 | Phase 1 Study of Epetraborole Tablets | Phase1 | Healthy Volunteers | Completed | 2021-06-10 | 2022-02-26 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | MAC Lung Disease | TERMINATED | NCT05327803 |
| Epetraborole | Other | Phase PHASE2 | MAC Lung Disease | TERMINATED | NCT05327803 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE1 | Renal Insufficiency | COMPLETED | NCT05283746 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Epetraborole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Epetraborole and matching placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04892641 |
| Epetraborole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04892641 |
| Placebo | Other | Phase PHASE2 | MAC Lung Disease | TERMINATED | NCT05327803 |
| Epetraborole | Other | Phase PHASE2 | MAC Lung Disease | TERMINATED | NCT05327803 |
| Observational Study | Other | Preclinical | Melioidosis | COMPLETED | NCT06089668 |
| Placebo | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |
| Epetraborole | Other | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT07024589 |
| AN2-502998 | DRUG | Phase PHASE1 | Healthy Volunteers | RECRUITING | NCT07024589 |
| Observational Study | OTHER | Preclinical | Melioidosis | COMPLETED | NCT06089668 |
| Moxifloxacin | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Epetraborole and matching placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05995444 |
| Placebo | DRUG | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |
| Epetraborole | DRUG | Phase PHASE2 | Mycobacterium Abscessus Infection | NOT_YET_RECRUITING | NCT07301320 |